乌苯美司联合同步放化疗治疗老年局部晚期喉癌的临床疗效

目的 探究乌苯美司联合同步放化疗治疗老年局部晚期喉癌的临床疗效,为进一步的临床应用提供理论依据.方法 前瞻性选取川北医学院附属医院2012年4月至2015年3月收治的老年局部晚期喉癌患者102例,按随机数字表法将其分为观察组和对照组,每组各51例.对照组患者采用同步放化疗方案,观察组患者在同步放化疗的基础上加用乌苯美司...

The clinical effect of ubenimex combined with concurrent radiotherapy and chemotherapy in the treatment of local advanced laryngeal cancer in the elderly

Objective To explore the clinical efficacy of ubenimex combined with concurrent radiotherapy and chemotherapy in the treatment of local advanced laryngeal cancer in the elderly,so as to provide theoretical basis for further clinical application.Methods From April 2012 to March 2015,102 elderly patients with locally advanced laryngeal cancer were randomly divided into two groups:the observation group and the control group.The patients in group B received concurrent radiotherapy and chemotherapy,while those in group A received ubenimex Capsule on the basis of concurrent radiotherapy and chemotherapy.The short-term clinical effect,immune function,adverse reactions and 5-year survival of the two groups were observed.Results There was no significant difference between the two groups(P>0.05).The levels of peripheral blood CD3⁺,CD4⁺,CD4⁺/CD8⁺and NK cells in the two groups were significantly higher than before treatment,while the levels of CD8⁺were significantly lower than those before treatment(P<0.05);And one month after treatment,the changes in peripheral blood immune indexes of the observation group were better than those of the control group,the differences were statistically significant(P<0.05).The incidence of leucopenia,thrombocytopenia,nausea and vomiting,liver and kidney function damage and throat reaction in the observation group was lower than that in the control group(P<0.05).The median survival time of observation group was 45 months(95%CI:40.15-49.85),and that of control group was 32 months(95%CI:26.94-37.06).The median survival time of the observation group was higher than that of the control group(P=0.001).The 5-year survival rate of observation group was 27.03%(10/37),and that of the control group was 6.67%(3/45).The 5-year survival rate of observation group was higher than that of the control group (P<0.05).Conclusion Ubenimex combined with concurrent radiotherapy and chemotherapy can not only enhance the immunity of the elderly patients with local advanced laryngeal cancer,reduce the adverse reactions of radiotherapy and chemotherapy,but also improve the 5-year survival rate of the patients,which is worthy of clinical promotion.